Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

Similar Items

• International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols
  od: Waheed, Sarah, i dr.
  Izdano: (2010)
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
  od: Hoering, Antje, i dr.
  Izdano: (2009)
• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
  od: van Rhee, Frits, i dr.
  Izdano: (2010)
• Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
  od: Nair, Bijay, i dr.
  Izdano: (2009)
• Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms
  od: Barlogie, Bart, i dr.
  Izdano: (2010)